New 'Biological CAR-T' drug aims to tame stubborn autoimmune diseases
NCT ID NCT06888960
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 40 times
Summary
This early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus and rheumatoid arthritis that haven't responded to standard treatments. CC312 works like a 'biological CAR-T' by guiding immune cells to attack and deplete faulty B cells. The study uses a low starting dose to reduce the risk of serious side effects like cytokine release syndrome, then gives a higher dose to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China, 300030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.